Falgá Conxita, Capdevila Josep Antón, Soler Silvia, Rabuñal Ramón, Sánchez Muñoz-Torrero Juan Francisco, Gallego Pedro, Monreal Manuel
Servicio de Medicina Interna, Consorci Sanitari del Maresme, Mataró, Spain.
Thromb Haemost. 2007 Oct;98(4):771-6.
There is little information on the clinical outcome of patients with venous thromboembolism and renal insufficiency. RIETE is an ongoing, prospective registry of consecutive patients with acute, objectively confirmed, symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE). In this analysis we analyzed the three-month outcome in patients with creatinine clearance (CrCl) <30 ml/min. As of March 2007, 1,037 of the 18,251 (5.7%) patients enrolled in RIETE had CrCl <30 ml/min. During the three-month study period these patients had an increased incidence of fatal bleeding, fatal PE, and overall death compared to those with CrCl >30 ml/min. Of the 579 patients presenting with clinically overt PE, 52 (9.0%) died of the initial PE, 13 (2.2%) of recurrent PE, and nine (1.6%) died of bleeding complications. During the first 15 days of therapy the 10% incidence of fatal PE was 10-fold their 1.0% of fatal bleeding. From day 16 to 90, the 1.0% rate of fatal PE was not significantly higher than the 0.5% of fatal bleeding. Of the 458 DVT patients with CrCl <30 ml/min, 14 (3.1%) had fatal bleeding and only one (0.2%) died of PE. In patients with CrCl <30 ml/min presenting with clinically overt PE the main threat is PE itself. On the contrary, in those with DVT the main threat is bleeding.
关于静脉血栓栓塞症和肾功能不全患者的临床转归,相关信息较少。RIETE是一项正在进行的前瞻性登记研究,纳入连续的急性、经客观证实的有症状的深静脉血栓形成(DVT)或肺栓塞(PE)患者。在本分析中,我们分析了肌酐清除率(CrCl)<30 ml/分钟患者的三个月转归情况。截至2007年3月,RIETE登记的18251例患者中有1037例(5.7%)CrCl<30 ml/分钟。在三个月的研究期间,与CrCl>30 ml/分钟的患者相比,这些患者致命性出血、致命性PE及总体死亡的发生率更高。在579例有临床明显PE的患者中,52例(9.0%)死于初始PE,13例(2.2%)死于复发性PE,9例(1.6%)死于出血并发症。在治疗的前15天,致命性PE的发生率为10%,是致命性出血发生率1.0%的10倍。从第16天到90天,致命性PE的发生率为1.0%,并不显著高于致命性出血的发生率0.5%。在458例CrCl<30 ml/分钟的DVT患者中,14例(3.1%)发生致命性出血,仅1例(0.2%)死于PE。在CrCl<30 ml/分钟且有临床明显PE的患者中,主要威胁是PE本身。相反,在有DVT的患者中,主要威胁是出血。